Use of docetaxel and carboplatin for patients with non-small-cell lung cancer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Docetaxel (Taxotere) and carboplatin (Paraplatin) have each demonstrated significant activity in non-small-cell lung cancer. The taxanes have favorable interactions with platinum compounds, both in vivo and in vitro. Thus, we combined docetaxel and carboplatin in a phase I trial to establish the maximum tolerated doses (MTD) and toxicity profile. Results from the phase I trial in patients with nonhematologic solid tumors indicate that this combination is well tolerated. The MTD of docetaxel in combination with carboplatin (target area under the curve, 6 mg/mL · min) is 90 mg/m 2 without granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen]) support and 100 mg/m 2 with G-CSF support. Based on the preliminary results of the phase I study, the combination of docetaxel and carboplatin is presently being evaluated in a phase H study in patients with advanced non- small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)31-33
Number of pages3
JournalOncology
Volume11
Issue number7 SUPPL.
StatePublished - 1997

Fingerprint

docetaxel
Carboplatin
Non-Small Cell Lung Carcinoma
Granulocyte Colony-Stimulating Factor
Maximum Tolerated Dose
Platinum Compounds
Taxoids
Area Under Curve

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{b2366088e717499fb32efbd637073023,
title = "Use of docetaxel and carboplatin for patients with non-small-cell lung cancer",
abstract = "Docetaxel (Taxotere) and carboplatin (Paraplatin) have each demonstrated significant activity in non-small-cell lung cancer. The taxanes have favorable interactions with platinum compounds, both in vivo and in vitro. Thus, we combined docetaxel and carboplatin in a phase I trial to establish the maximum tolerated doses (MTD) and toxicity profile. Results from the phase I trial in patients with nonhematologic solid tumors indicate that this combination is well tolerated. The MTD of docetaxel in combination with carboplatin (target area under the curve, 6 mg/mL · min) is 90 mg/m 2 without granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen]) support and 100 mg/m 2 with G-CSF support. Based on the preliminary results of the phase I study, the combination of docetaxel and carboplatin is presently being evaluated in a phase H study in patients with advanced non- small-cell lung cancer.",
author = "Chandra Belani",
year = "1997",
language = "English (US)",
volume = "11",
pages = "31--33",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7 SUPPL.",

}

Use of docetaxel and carboplatin for patients with non-small-cell lung cancer. / Belani, Chandra.

In: Oncology, Vol. 11, No. 7 SUPPL., 1997, p. 31-33.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of docetaxel and carboplatin for patients with non-small-cell lung cancer

AU - Belani, Chandra

PY - 1997

Y1 - 1997

N2 - Docetaxel (Taxotere) and carboplatin (Paraplatin) have each demonstrated significant activity in non-small-cell lung cancer. The taxanes have favorable interactions with platinum compounds, both in vivo and in vitro. Thus, we combined docetaxel and carboplatin in a phase I trial to establish the maximum tolerated doses (MTD) and toxicity profile. Results from the phase I trial in patients with nonhematologic solid tumors indicate that this combination is well tolerated. The MTD of docetaxel in combination with carboplatin (target area under the curve, 6 mg/mL · min) is 90 mg/m 2 without granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen]) support and 100 mg/m 2 with G-CSF support. Based on the preliminary results of the phase I study, the combination of docetaxel and carboplatin is presently being evaluated in a phase H study in patients with advanced non- small-cell lung cancer.

AB - Docetaxel (Taxotere) and carboplatin (Paraplatin) have each demonstrated significant activity in non-small-cell lung cancer. The taxanes have favorable interactions with platinum compounds, both in vivo and in vitro. Thus, we combined docetaxel and carboplatin in a phase I trial to establish the maximum tolerated doses (MTD) and toxicity profile. Results from the phase I trial in patients with nonhematologic solid tumors indicate that this combination is well tolerated. The MTD of docetaxel in combination with carboplatin (target area under the curve, 6 mg/mL · min) is 90 mg/m 2 without granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen]) support and 100 mg/m 2 with G-CSF support. Based on the preliminary results of the phase I study, the combination of docetaxel and carboplatin is presently being evaluated in a phase H study in patients with advanced non- small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0030794978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030794978&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030794978

VL - 11

SP - 31

EP - 33

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7 SUPPL.

ER -